ALLO Live signals | Maximize Profits with Getagraph.com

SELL 99573 min ago

@ $4.90

Issued: 14 Feb 2024 @ 15:50

Return: -31.15%

Previous signal: Feb 14 - 13:56

Previous signal: Buy

Return: 2.30 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...

Stats
Today's Volume	1.58M
Average Volume	2.28M
Market Cap	569.84M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.390 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.610
ATR14	$0.00600 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Chang David D	Sell	53 393	Common Stock
2024-01-30	Parker Geoffrey M.	Buy	190	Common Stock
2024-01-25	Moore Timothy L.	Buy	341 515	Stock Option (Right to buy)
2024-01-25	Moore Timothy L.	Buy	96 600	Common Stock
2024-01-25	Douglas Earl Martin	Buy	41 800	Common Stock

INSIDER POWER
93.70
Last 94 transactions
Buy: 32 956 491 \| Sell: 32 061 810

Volume Correlation

Long: -0.51 (weak negative)

Short: -0.45 (neutral)

Signal:(26.235) Neutral

Allogene Therapeutics Inc Correlation

10 Most Positive Correlations
HEPA	0.96
TNYA	0.956
ULCC	0.955
NGM	0.953
RIDE	0.953
JBLU	0.953
IMBI	0.952
TCMD	0.952
FNCH	0.951
ALLR	0.95

10 Most Negative Correlations
SKYA	-0.962
LEGA	-0.957
BRIV	-0.955
ADAL	-0.953
TBSAU	-0.951
TBSA	-0.95
CRZN	-0.949
LDHA	-0.949
FTPA	-0.949
AGGR	-0.949

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Allogene Therapeutics Inc Correlation - Currency/Commodity

-0.53
( weak negative )

-0.20
( neutral )

0.00
( neutral )

-0.30
( neutral )

Allogene Therapeutics Inc Financials

Annual	2023
Revenue:	$95 000.00
Gross Profit:	$95 000.00 (100.00 %)
EPS:	$-2.09

Q4	2023
Revenue:	$21 000.00
Gross Profit:	$21 000.00 (100.00 %)
EPS:	$-0.510

Q3	2023
Revenue:	$43 000.00
Gross Profit:	$-3.53M (-8 206.98 %)
EPS:	$-0.370

Q2	2023
Revenue:	$44 000.00
Gross Profit:	$-3.75M (-8 520.45 %)
EPS:	$-0.530

Financial Reports:

No articles found.

Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.